{"id":1448,"date":"2010-03-01T20:43:16","date_gmt":"2010-03-02T01:43:16","guid":{"rendered":"http:\/\/blogs.nejm.org\/cardioexchange\/what-should-the-relationship-be-between-pharmaceutical-companies-and-fellows\/"},"modified":"2011-07-19T17:44:12","modified_gmt":"2011-07-19T21:44:12","slug":"what-should-the-relationship-be-between-pharmaceutical-companies-and-fellows","status":"publish","type":"post","link":"https:\/\/blogs.nejm.org\/cardioexchange\/2010\/03\/01\/what-should-the-relationship-be-between-pharmaceutical-companies-and-fellows\/","title":{"rendered":"What Should the Relationship Be Between Pharmaceutical Companies and Fellows?"},"content":{"rendered":"

Recent publications, including a scientific advisory in Circulation<\/em><\/a> on rosiglitazone, the industry response<\/a> to a Senate Finance Committee\u2019s report on the drug, as well as a commentary in Forbes<\/em> by Harlan Krumholz<\/a>, have made me consider further the role that pharmaceutical companies play in the context of fellowship training programs.<\/p>\n

The relationships between training programs and these companies, and their potential influence, have undergone significant changes over the past several years. Practices that were in place when I was in training (about 10 years ago) no longer exist. Beyond industry’s self-imposed restrictions, many medical institutions have placed significant restrictions, both personal and financial, on the access to fellows by pharmaceutical companies and their representatives. Still, pharmaceutical companies have many avenues by which they can influence fellows. Some of these may be fairly trivial, such as providing lunch or breakfast for conferences, and others reach further, such as funding support for CME conferences, grant support for career development, and salary support for fellowship positions.<\/p>\n

Restrictions, including those here at my own institution, have greatly changed the access that pharmaceutical companies and their representatives have with fellows, but whether these restrictions have changed industry influence remains unclear. Several issues here merit discussion. Are you, as fellows, comfortable with the role that pharmaceutical companies have in your training?  Are the imposed changes adequate or unnecessary?  Or do they not go far enough?<\/p>\n

Issues concerning the role of pharmaceutical companies in your research also merit discussion. As you advance towards junior faculty positions, what role should industry support have in your research and career development? In terms of grant applications, how do you perceive funding support from industry?  Are you leery of clinical trials because of the influence of pharmaceutical companies? We are eager to hear what you think.<\/p>\n","protected":false},"excerpt":{"rendered":"

Recent publications, including a scientific advisory in Circulation on rosiglitazone, the industry response to a Senate Finance Committee\u2019s report on the drug, as well as a commentary in Forbes by Harlan Krumholz, have made me consider further the role that pharmaceutical companies play in the context of fellowship training programs. The relationships between training programs and […]<\/p>\n","protected":false},"author":202,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-1448","post","type-post","status-publish","format-standard","hentry","category-general"],"_links":{"self":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/1448","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/users\/202"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/comments?post=1448"}],"version-history":[{"count":0,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/1448\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/media?parent=1448"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/categories?post=1448"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/tags?post=1448"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}